Last reviewed · How we verify
TSR-033
At a glance
| Generic name | TSR-033 |
|---|---|
| Also known as | LAG-3 |
| Sponsor | Tesaro, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study of TSR-022 in Participants With Advanced Solid Tumors (AMBER) (PHASE1)
- Study of TSR-033 With an Anti-programmed Cell Death-1 Receptor (PD-1) in Participants With Advanced Solid Tumors (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- TSR-033 CI brief — competitive landscape report
- TSR-033 updates RSS · CI watch RSS
- Tesaro, Inc. portfolio CI